[1] Huang Q, Du J, Cheng SQ, et al.Progress of proton pump inhibitors using in cancer patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics(中国临床药理学与治疗学), 2018, 23(10): 105-113. [2] Smelick GS, Heffron TP, Chu L, et al.Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development[J] . Mol. Pharm, 2013, 10(11): 4055-4062. [3] Zhang S, Wang MX, Feng ZY, et al.Progress on pharmacokinetic interaction of targeted antitumor drugs[J]. China Pharmacy(中国药房), 2016, 27(20): 2871-2874. [4] Ding YF, Zhong DF.Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors[J]. Acta Pharmaceutica Sinica(药学学报), 2013, 48(7): 1080-1090. [5] Schlichtig K, Dürr P, Dörje F, et al.New oral anti-cancer drugs and medication safety[J] . Dtsch Arztebl Int, 2019, 116(46): 775-782. [6] Kumarakulasinghe NB, Syn N, Soon YY, et al.EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction[J]. Oncotarget, 2016, 7: 85542-85550. [7] Kletzl H, Giraudon M, Abt M, et al.Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: Omeprazole and ranitidine[J]. Anti-Cancer Drugs, 2015, 26(5): 565-72. [8] Ohgami M, Kaburagi T, Kurosawa A, et al.Effects of proton pump inhibitor coadministration on the plasma concentration of erlotinib in patients with non-small cell lung cancer[J]. Ther Drug Monit, 2018, 40(6): 699-704. [9] Chu MP, Ghosh S, Chambers CR, et al.Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer[J]. Clinical Lung Cancer, 2015, 16(1): 33-39. [10] Heine RT, Fanggiday JC, Lankheet NAG, et al.Erlotinib and pantoprazole: a relevant interaction or not?[J]. British Journal of Clinical Pharmacology, 2010, 70(6): 908-911. [11] Yasumuro O, Uchida S, Kashiwagura Y, et al.Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats[J]. Xenobiotica, 2018, 48(11): 1106-1112. [12] Niho S, You Y, Zenke k, et al. Clinical impact of gastric acid-suppressing medication use on the efficacy of erlotinib and gefitinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations[J] . Clin Lung Cancer, 2016, 17(5), 412-418. [13] Fang YH, Yang YH, Hsieh MJ, et al.Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment-a nationwide population-based study[J]. Cancer Manag Res, 2019, 11: 8539-8546. [14] Vishwanathan K, Dickinson PA, Bui K, et al.The Effect of food or omeprazole on the pharmacokinetics of osimertinib in patients with non-small-cell lung cancer and in healthy volunteers[J]. J Clin Pharmacol, 2018, 58(4): 474-484. [15] Hamilton G, Rath B, Burghuber O.Pharmacokinetics of crizotinib in NSCLC patients[J]. Expert Opinion on Drug Metabolism & Toxicology, 2015, 11(5): 835-842. [16] Hirota T, Muraki S, Ieiri I.Clinical pharmacokinetics of anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer[J]. Clinical Pharmacokinetics, 2019, 58(4): 403-420. [17] Hong Y, Passos VQ, Huang PH, et al.Population pharmacokinetics of ceritinib in adult patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase[J]. The Journal of Clinical Pharmacology, 2017, 57(5): 652-662. [18] Lau YY, Gu W, Lin T, et al.Assessment of drug drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer[J]. Cancer Chemotherapy and Pharmacology, 2017, 79(6): 1119-1128. [19] Escudier DB, Gore M.Axitinib for the management of metastatic renal cell carcinoma[J]. Drugs in R & D, 2011, 11(2): 113-126. [20] Rugo HS.Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results[J]. Journal of Clinical Oncology, 2005, 23(24): 5474-5483. [21] Lalani AKA, Mckay RR, Lin X, et al.Proton pump inhibitors and survival outcomes in patients with metastatic renal cell carcinoma[J]. Clin Genitourin Cancer, 2017, 15(6): 724-732. [22] Tan AR, Gibbon DG, Stein MN, et al.Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors[J]. Cancer Chemotherapy and Pharmacology, 2013, 71(6): 1635-1643. [23] Mcalister RK, Aston J, Pollack M, et al.Effect of concomitant pH-elevating medications with pazopanib on progression-free survival and overall survival in patients with metastatic renal cell carcinoma[J]. Oncologist, 2018, 23(6): 686-692. [24] Koch KM, Young-Hyuck I, Sung-Bae K, et al.Effects of esomeprazole on the pharmacokinetics of lapatinib in breast cancer patients[J]. Clin Pharmacol Drug Dev, 2013, 2(4): 336-341. [25] Ruiz-Garcia A, Masters JC, Laure MDC, et al.Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers[J]. The Journal of Clinical Pharmacology, 2016, 56(2): 223-230. [26] Egorin MJ, Shah DD, Christner SM, et al.Effect of a proton pump inhibitor on the pharmacokinetics of imatinib[J]. British Journal of Clinical Pharmacology, 2009, 68(3): 370-374. [27] White DL, Eadie LN, Saunders VA, et al.Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells[J]. Leukemia, 2013, 27(5): 1201-1204. [28] Xu H, Ma LL, Xu W, et al.A Chinese multi-center study on the significance of monitoring imatinib plasma concentration in patients with gastrointestinal stromal tumor before and after administration[J]. Chinese Journal of Gastrointestinal Surgery(中华胃肠外科杂志), 2016, 19(11): 1271-1276. [29] Récoché I, Rousseau V, Bourrel R, et al.Drug-drug interactions with imatinib: An observational study[J]. Medicine (Baltimore), 2016, 95(40): e5076. [30] Hořínková J, Šíma M, Slanař O.Pharmacokinetics of dasatinib[J]. Prague Med Rep, 2019, 120(2): 52-63. [31] Takahashi N, Miura M, Niioka T, et al.Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmaco-kinetics in Japanese leukemia patients[J]. Cancer Chemother Pharmacol, 2012, 69(4): 999-1004. [32] Yago MR, Frymoyer A, Benet LZ, et al.The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria[J]. The AAPS Journal, 2014, 16(6): 1358-1365. [33] Santiago O, Vicente EV, Gómez-Centurión Ignacio, et al.Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?[J]. Ann Hematol, 2018, 97(11): 2089-2098. [34] Yin OQ, Gallagher N, Fischer D, et al.Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib.[J]. J Clin Pharmacol, 2010, 50(8): 960-967. [35] Yin OQP, Frank J.Giles. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia[J]. Cancer Chemotherapy and Pharmacology, 2012, 70(2): 345-350. [36] Abdelgalil AA, Alkahtani HM, Al-Jenoobi FI, et al.Sorafenib[J]. Profiles Drug Subst Excip Relat Methodol, 2019, 44: 239-266. [37] Lind JSW, Dingemans AMC, Groen HJM, et al.A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer[J]. Clinical Cancer Research, 2010, 16(11): 3078-3087. [38] Flaherty KT, Lathia C, Frye RF, et al.Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study[J]. Cancer Chemother Pharmacol, 2011, 68(5): 1111-1118. [39] Bilbao-Meseguer I, Jose BS, Lopez-Gimenez LR, et al.Drug interactions with sunitinib[J]. J Oncol Pharm Pract, 2015, 21(1): 52-66. [40] Ha VH, Ngo M, Chu MP, et al.Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer?[J]. Journal of Oncology Pharmacy Practice, 2015, 21(3): 194-200. [41] Femke MDM, Koen GAMH, Mirjam DW, et al.Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib: a randomized crossover pharmac-okinetic study[J]. Clin Pharmacol Ther, 2019, 105(6): 1456-1461. [42] Budha NR, Frymoyer A, Smelick GS, et al.Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?[J]. Clin Pharmacol Ther, 2012, 92(2): 203-213. |